AZD5335

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Ovarian CancerFallopian Tube CancerEpithelial Ovarian Cancer

232 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

1

Avastin

Roche

Phase 3

882

Gemzar

Johnson & Johnson

Phase 3

333

Keytruda

Merck & Co.

Phase 3

284

Hycamtin

MMeitheal

Phase 3

265

Cytoxan

BBaxter Healthcare Corporation

Phase 3

246

Adriamycin

Pfizer

Phase 3

87

Femara

Novartis

Phase 3

88

Imfinzi

AstraZeneca

Phase 3

89

Opdivo

Bristol-Myers Squibb

Phase 3

810

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

23Show 42 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Ovarian Cancer1 trial

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Recruiting·AstraZeneca·Preclinical·NCT05797168·602 enrolled

Epithelial Ovarian Cancer1 trial

A Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator's Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

Recruiting·AstraZeneca·Phase 3·NCT07218809·1,100 enrolled

Fallopian Tube Cancer1 trial

An Open-label, Fixed Sequence Phase I Study to Evaluate the Effect of Itraconazole (a Strong CYP3A Inhibitor) on the Pharmacokinetics of AZ14170132, the TOP1 Inhibitor Payload of the Antibody Drug Conjugate AZD5335, in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recruiting·AstraZeneca·Phase 1·NCT07402915·24 enrolled

Details

Drug Info

Related News